News & Publications

  • WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

    • 8.30.2017

    On August 10, 2017, Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a $60 million Series E preferred stock financing.

    WilmerHale represented Apellis in this transaction, with a team led by Stuart Falber and included Mhairi Immermann and Alicia Lee.

    Read Apellis' press release

    See other News & Publications related to:

    See related industries:

    Life Sciences